3-Methyl-2-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1h-indole
- $167 - $3998
- Product name: 3-Methyl-2-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1h-indole
- CAS: 1072812-35-1
- MF: C15H20BNO2
- MW: 257.14
- EINECS:
- MDL Number:
- Synonyms:3-Methyl-2-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1h-indole;3-Methyl-1H-indole-2-boronic acid pinacol ester;3-Methyl-1H-indole-2-boronic acid picol ester;1H-Indole, 3-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
3 prices
Selected condition:
Brand
- Alichem
- Chemenu
Package
- 250mg
- 1g
- ManufacturerAlichem
- Product number1072812351
- Product description3-Methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole
- Packaging1g
- Price$733.95
- Updated2021-12-16
- Buy
- ManufacturerChemenu
- Product numberCM204654
- Product description3-Methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole 98%
- Packaging250mg
- Price$167
- Updated2021-12-16
- Buy
- ManufacturerChemenu
- Product numberCM204654
- Product description3-Methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole 98%
- Packaging1g
- Price$466
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Alichem | 1072812351 | 3-Methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole | 1g | $733.95 | 2021-12-16 | Buy |
Chemenu | CM204654 | 3-Methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole 98% | 250mg | $167 | 2021-12-16 | Buy |
Chemenu | CM204654 | 3-Methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole 98% | 1g | $466 | 2021-12-16 | Buy |
Properties
Boiling point :408.1±33.0 °C(Predicted)
Density :1.09±0.1 g/cm3(Predicted)
pka :17.06±0.30(Predicted)
Density :1.09±0.1 g/cm3(Predicted)
pka :17.06±0.30(Predicted)
Safety Information
Symbol(GHS): | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | |||||||||||||||||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
Precautionary statements: |
|